C4 Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €1.31B +932.1% €240.30M -522.5% 18.4% +0.63 pp N/A N/A
    (estimated) €126.76M +630.2% -€56.87M -50.8% -44.9% +6.2 pp N/A N/A
    (estimated) €17.36M -0.6% -€115.51M -0.8% -665.4% +0.013 pp N/A N/A
    (estimated) €17.47M -20.4% -€116.47M +24.4% -666.6% -2.4 pp N/A N/A
    (estimated) €21.95M -28.4% -€93.60M +3.2% -426.4% -1.3 pp N/A N/A
    €30.66M +71.4% -€90.73M -20.5% -296.0% +3.4 pp -€55.98M -38.2% -182.6% +3.2 pp
    €17.88M -33.3% -€114.15M +4.7% -638.3% -2.3 pp -€90.57M +4.7% -506.5% -1.8 pp
    €26.79M -32.1% -€108.99M +47.0% -406.8% -2.2 pp -€86.54M +17.2% -323.0% -1.4 pp
    €39.45M +37.9% -€74.13M +29.7% -187.9% +0.12 pp -€73.82M +28.7% -187.2% +0.13 pp
    €28.60M +55.3% -€57.15M +94.5% -199.8% -0.40 pp -€57.38M -216.9% -200.6% -4.7 pp
    €18.42M +10.4% -€29.38M +117.0% -159.5% -0.78 pp €49.08M -498.6% 266.4% +3.4 pp
    €16.68M -€13.54M -81.1% -€12.31M -73.8%

    Notifications